Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.63 |
| ▸ | HTR2A | P28223 | 6/20 | 0.63 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236331 | 0.85 | KCNH2 (0.48) | SLC6A4KCNH2HTR2ASLC6A2TMEM97 | |
| SCHEMBL4236215 | 0.83 | KCNH2 (0.47) | SLC6A4KCNH2HTR2AMRGPRX4SLC6A2 | |
| SCHEMBL10656350 | 0.83 | SLC6A4 (0.48) | SLC6A4KCNH2HTR2ASLC6A2PDE2A | |
| SCHEMBL4242538 | 0.81 | KCNH2 (0.46) | SLC6A4KCNH2HTR2ASLC6A2TMEM97 | |
| SCHEMBL4241050 | 0.80 | KCNH2 (0.45) | SLC6A4KCNH2HTR2ASLC6A2TMEM97 | |
| SCHEMBL13840653 | 0.80 | SLC6A4 (0.54) | SLC6A4KCNH2HTR2AMRGPRX4SLC6A2 | |
| SCHEMBL5325645 | 0.80 | SLC6A4 (0.54) | SLC6A4KCNH2HTR2AMRGPRX4SLC6A2 | |
| SCHEMBL10050765 | 0.79 | SLC6A4 (0.46) | SLC6A4KCNH2HTR2AMRGPRX4SLC6A2 | |
| SCHEMBL4235855 | 0.79 | KCNH2 (0.45) | SLC6A4KCNH2HTR2ASLC6A2TMEM97 | |
| SCHEMBL5837868 | 0.79 | HTR2A (1.00) | SLC6A4KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| WO-2015089137-A1 | ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| CN-1062555-C | Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same | HOECHST AG (DE) | 2001-02-28 | — | — | CN | disclosed |
| EP-0748795-B1 | Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them | HOECHST AG (DE) | 2000-08-23 | — | — | EP | disclosed |
| US-6022899-A | EFFECTIVE INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-08 | — | — | US | disclosed |
| US-5753710-A | INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | disclosed |
| CN-1145360-A | Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same | HOECHST AG (DE) | 1997-03-19 | — | — | CN | disclosed |
| EP-0748795-A2 | Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | SLC6A4 134/4885KCNH2 2633/4885HTR2A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.